TOLTERODINE CRESCENT

2). In case of troublesome side-effects the dose may be reduced from 4 mg to 2 mg once daily. The prolonged-release capsules can be taken with or without food and must be swallowed whole. 1). 1). Therefore, Tolterodine is not recommended for children.

Due to the pharmacological effect of tolterodine it may cause mild to moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and dry eyes. The table below reflects the data obtained with Tolterodine in clinical trials and from post marketing experience.

7 % of placebo-treated patients. g. confusion, disorientation, delusion) have been reported after tolterodine therapy was initiated in patients taking cholinesterase inhibitors for the treatment of dementia. 4 %). 1) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

g. 1). The clinical relevance of these findings is unclear and will depend on individual patient risk factors and susceptibilities present. e. g. g. amiodarone, sotalol) anti-arrhythmics. 1). 5, Interactions). As with all treatments for symptoms of urgency and urge incontinence, organic reasons for urge and frequency should be considered before treatment.

Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

1. Tolterodine is contraindicated in patients with - Urinary retention - Uncontrolled narrow angle glaucoma - Myasthenia gravis - Severe ulcerative colitis - Toxic megacolon